Ricovr Healthcare
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Founded Year
2017Stage
Debt | AliveTotal Raised
$3.26MLast Raised
$260K | 1 yr agoAbout Ricovr Healthcare
RICOVR Healthcare is the creator of the XALIVA rapid diagnostics platform that provides high-quality, rapid diagnostics results using a small amount of saliva. The company’s product pipeline includes rapid point-of-care tests for Covid-19, THC & drugs-of-abuse, and infectious diseases. The company's patented biosensor platform uses a small drop of saliva to provide high-quality, cost-effective results in approximately five minutes, enabling employers, healthcare systems, and law enforcement to carry out cost-effective, non- invasive workplace and roadside testing.
Ricovr Healthcare Headquarter Location
252 Nassau St
Princeton, New Jersey, 08542,
United States
Expert Collections containing Ricovr Healthcare
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ricovr Healthcare is included in 5 Expert Collections, including Medical Devices.
Medical Devices
8,452 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
3,095 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Digital Health
13,084 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health IT
7,900 items
Clinical Encounter Tech
897 items
Latest Ricovr Healthcare News
Apr 19, 2021
RICOVR Healthcare announced that it has raised $1.5 million in funding to commercialize its point-of-care testing device for THC and COVID-19. April 19, 2021 09:00 ET Princeton, New Jersey, UNITED STATES Princeton, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- RICOVR Healthcare , creator of the XALIVATM rapid diagnostics platform, announced that it has raised $1.5 million in funding to commercialize its point-of-care testing device for THC and COVID-19. The Company’s novel biosensor platform uses a small amount of saliva to provide lab-quality, quantified, low-cost diagnostics in approximately five minutes. This successful round of funding is further evidence the market continues to search for solutions that can simplify THC and COVID-19 testing procedures and provide highly accurate data quickly and affordably. RICOVR has received multiple awards for the novel XALIVA platform, and this funding round will primarily drive commercial execution and go-to-market. ”It’s affirming to have the support of our investors as we look to launch RICOVR’s innovative biosensor platform XALIVA. The capital, knowledge, and network our investors bring to RICOVR Healthcare will enable us to achieve our goal. Pre-validation testing results of the device have shown the true potential of our saliva-based platform by successfully identifying various biomarkers. Our technology is set to disrupt the huge and fast-growing drug testing and diagnostic market,” said Dr. Himanshu Bhatia, CEO and Founder of RICOVR. Piyush Sadana, COO and Co-Founder of RICOVR said, “We are excited to move towards commercialization of XALIVA with this latest round of investment. Multiple employers in construction, transportation, retail, and manufacturing industries have expressed interest in our device to safely reopen workplaces and test for THC. In addition, as states are legalizing recreational marijuana, law enforcement agencies are looking for a convenient and accurate roadside test to pre-screen for drivers under the influence. The investment proceeds will be used to complete RICOVR’s platform development, scale-up production capabilities, and drive successful commercialization.” RICOVR has now raised a total of $3.0 million. The new funding was led by Achari Ventures, with participation from Halley Venture Partners and strategic investors. Vikas Desai, Managing Partner of Achari Ventures added, “We’re excited by the initial findings around the efficacy of the XALIVA platform to solve a critical unmet need in the marketplace. By focusing on large labor forces, we believe the company can accelerate commercialization at an attractive price point for end customers and solve their pre-screening needs in a more efficient manner.” About RICOVR RICOVR Healthcare is the creator of the XALIVA rapid diagnostics platform that provides high-quality, rapid diagnostics results using a small amount of saliva. Company’s product pipeline includes rapid point-of-care tests for Covid-19, THC & drugs-of-abuse, and infectious diseases. The Company boasts a distinguished advisory board and management team of scientists and engineers committed to making a positive impact on society. In addition, the company has strong partnerships with leading research institutions and medical device manufacturing companies around the globe. To learn more about RICOVR Healthcare, visit https://www.ricovr.com/ . Media contact for RICOVR Healthcare
Ricovr Healthcare Web Traffic
Ricovr Healthcare Rank
When was Ricovr Healthcare founded?
Ricovr Healthcare was founded in 2017.
Where is Ricovr Healthcare's headquarters?
Ricovr Healthcare's headquarters is located at 252 Nassau St, Princeton.
What is Ricovr Healthcare's latest funding round?
Ricovr Healthcare's latest funding round is Debt.
How much did Ricovr Healthcare raise?
Ricovr Healthcare raised a total of $3.26M.
Who are the investors of Ricovr Healthcare?
Investors of Ricovr Healthcare include Halley Venture Partners and Floret Ventures.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.